130 related articles for article (PubMed ID: 30965658)
1. Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?
Heller DR; Chiu AS; Farrell K; Killelea BK; Lannin DR
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30965658
[No Abstract] [Full Text] [Related]
2. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer molecular subtypes in oman: correlation with age, histology, and stage distribution - analysis of 542 cases.
Mehdi I; Monem AA; Al Bahrani B; Ramadhan FA
Gulf J Oncolog; 2014 Jan; 1(15):38-48. PubMed ID: 24610287
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for stage IV breast cancer at the time of presentation in Turkey.
Uyeturk U; Tatli AM; Gucuk S; Oksuzoglu B; Ulas A; Avci N; Ozbay MF; Gunduz S; Akinci MB; Salim DK; Sonmez OU; Akdag F; Ergenc H
Asian Pac J Cancer Prev; 2013; 14(12):7445-9. PubMed ID: 24460317
[TBL] [Abstract][Full Text] [Related]
5. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
6. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
Jemal A; Ward E; Thun MJ
Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
[TBL] [Abstract][Full Text] [Related]
7. Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.
Holloway CMB; Jiang L; Whitehead M; Racz JM; Groome PA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1769-1775. PubMed ID: 29909564
[TBL] [Abstract][Full Text] [Related]
8. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis.
Wu SG; Li H; Tang LY; Sun JY; Zhang WW; Li FY; Chen YX; He ZY
Tumour Biol; 2017 Jun; 39(6):1010428317705082. PubMed ID: 28653887
[TBL] [Abstract][Full Text] [Related]
9. Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography.
Jacklyn G; McGeechan K; Irwig L; Houssami N; Morrell S; Bell K; Barratt A
Breast Cancer Res Treat; 2017 Dec; 166(3):843-854. PubMed ID: 28822001
[TBL] [Abstract][Full Text] [Related]
10. Responding to the challenges of breast cancer in egypt and other arab countries.
El Saghir NS
J Egypt Natl Canc Inst; 2008 Dec; 20(4):309-12. PubMed ID: 20571588
[TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry.
Mattes MD; Bhatia JK; Metzger D; Ashamalla H; Katsoulakis E
J Breast Cancer; 2015 Jun; 18(2):143-8. PubMed ID: 26155290
[TBL] [Abstract][Full Text] [Related]
12. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
13. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
15. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer.
Bychkovsky BL; Guo H; Sutton J; Spring L; Faig J; Dagogo-Jack I; Battelli C; Houlihan MJ; Yeh TC; Come SE; Lin NU
Oncologist; 2016 Dec; 21(12):1495-1501. PubMed ID: 27551013
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
Sihto H; Lundin J; Lehtimäki T; Sarlomo-Rikala M; Bützow R; Holli K; Sailas L; Kataja V; Lundin M; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
Clin Cancer Res; 2008 Jul; 14(13):4103-10. PubMed ID: 18593987
[TBL] [Abstract][Full Text] [Related]
18. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer.
Helvie MA; Chang JT; Hendrick RE; Banerjee M
Cancer; 2014 Sep; 120(17):2649-56. PubMed ID: 24840597
[TBL] [Abstract][Full Text] [Related]
19. 20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes:
Milano AF
J Insur Med; 2019; 48(1):5-23. PubMed ID: 31609640
[No Abstract] [Full Text] [Related]
20. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
